Cardiovascular Systems Financial Statements ()
|
|
|
|
Report date
|
|
|
18.08.2022 |
03.11.2022 |
09.02.2023 |
|
09.02.2023 |
|
Currency
|
|
|
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
62.5 |
59.7 |
61.5 |
|
239.8 |
|
Operating Income, bln rub |
|
|
-9.49 |
-10.9 |
-8.53 |
|
-38.6 |
|
EBITDA, bln rub |
? |
|
-9.14 |
-9.02 |
-8.18 |
|
-35.6 |
|
Net profit, bln rub |
? |
|
-9.69 |
-10.6 |
-7.89 |
|
-37.9 |
|
|
OCF, bln rub |
? |
|
-9.83 |
-13.7 |
-3.55 |
|
-29.2 |
|
CAPEX, bln rub |
? |
|
1.000 |
0.688 |
2.04 |
|
4.52 |
|
FCF, bln rub |
? |
|
-10.8 |
-14.3 |
-5.59 |
|
-33.7 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
55.7 |
53.9 |
51.5 |
|
212.2 |
|
Cost of production, bln rub |
|
|
16.3 |
16.7 |
18.5 |
|
66.2 |
|
R&D, bln rub |
|
|
8.77 |
9.06 |
9.53 |
|
36.4 |
|
Interest expenses, bln rub |
|
|
0.407 |
0.406 |
0.404 |
|
1.63 |
|
|
Assets, bln rub |
|
|
322.7 |
312.0 |
311.5 |
|
311.5 |
|
Net Assets, bln rub |
? |
|
249.5 |
242.2 |
239.4 |
|
239.4 |
|
Debt, bln rub |
|
|
20.3 |
21.4 |
20.1 |
|
20.1 |
|
Cash, bln rub |
|
|
159.8 |
143.7 |
132.0 |
|
132.0 |
|
Net debt, bln rub |
|
|
-139.5 |
-122.3 |
-111.9 |
|
-111.9 |
|
|
Ordinary share price, rub |
|
|
14.4 |
13.9 |
13.6 |
|
13.6 |
|
Number of ordinary shares, mln |
|
|
39.3 |
39.6 |
39.7 |
|
39.7 |
|
|
Market cap, bln rub |
|
|
565 |
549 |
540 |
|
540 |
|
EV, bln rub |
? |
|
425 |
427 |
428 |
|
428 |
|
Book value, bln rub |
|
|
234 |
227 |
224 |
|
224 |
|
|
EPS, rub |
? |
|
-0.25 |
-0.27 |
-0.20 |
|
-0.95 |
|
FCF/share, rub |
|
|
-0.28 |
-0.36 |
-0.14 |
|
-0.85 |
|
BV/share, rub |
|
|
5.94 |
5.73 |
5.66 |
|
5.66 |
|
|
EBITDA margin, % |
? |
|
-14.6% |
-15.1% |
-13.3% |
|
-14.9% |
|
Net margin, % |
? |
|
-15.5% |
-17.8% |
-12.8% |
|
-15.8% |
|
FCF yield, % |
? |
|
-3.44% |
-5.12% |
-6.23% |
|
-6.23% |
|
ROE, % |
? |
|
-18.8% |
-16.4% |
-19.9% |
|
-15.8% |
|
ROA, % |
? |
|
-14.5% |
-12.7% |
-15.3% |
|
-12.2% |
|
|
P/E |
? |
|
-12.0 |
-13.8 |
-11.4 |
|
-14.3 |
|
P/FCF |
|
|
-29.0 |
-19.5 |
-16.0 |
|
-16.0 |
|
P/S |
? |
|
1.93 |
2.34 |
1.82 |
|
2.25 |
|
P/BV |
? |
|
2.42 |
2.42 |
2.41 |
|
2.41 |
|
EV/EBITDA |
? |
|
-10.0 |
-11.5 |
-9.47 |
|
-12.0 |
|
Debt/EBITDA |
|
|
3.29 |
3.30 |
2.47 |
|
3.14 |
|
|
R&D/CAPEX, % |
|
|
877.3% |
1 316% |
467.5% |
|
805.4% |
|
|
CAPEX/Revenue, % |
|
|
1.60% |
1.15% |
3.32% |
|
1.88% |
|
| Cardiovascular Systems shareholders |
